Calendario›GILD›IMMU 130
IMMU 130
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Ensayo de GILEAD SCIENCES, INC. en Cancer colorrectal metastasico.
Más ensayos de: Cáncer colorrectal metastásico.
- Fase
- Fase 2
- Estado
- Retirado antes de empezar
- Fin del objetivo primario
- ago 2015
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, abierto. Comenzó en sep 2013.
Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «No participants enrolled».
Qué mide
Safety (Safety will be measured routinely during the 6 months of administration and afterwards during follow-up for up to 5 years) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a Phase II trial to study the safety and efficacy of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer. Antibodies are proteins normally made by the immune system. They bind to substances that don't belong in the body to prevent harm to the body. The antibody in this study was designed to bind to a marker located on colorectal cancer tumors. The antibody was originally made from mouse proteins, but was changed in the laboratory to be more like human antibodies. This study will investigate how IMMU-130 acts for the treatment of colorectal cancer. The study is mainly being done to see if IMMU-130 is safe and effective.
Más ensayos de GILD
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Tenofovir DF | Fase 3 | En marcha, sin reclutar | ago 2017 (real) |
| Oral Lenacapavir · CAPELLA | Fase 2/3 | En marcha, sin reclutar | oct 2020 (real) |
| Sacituzumab Govitecan-hziy | Fase 2 | En marcha, sin reclutar | ago 2021 (real) |
| Sacituzumab Govitecan-hziy · EVOKE-01 | Fase 3 | En marcha, sin reclutar | nov 2023 (real) |
| ISL | Fase 2 | En marcha, sin reclutar | dic 2023 (real) |
| Oral Lenacapavir · PURPOSE 1 | Fase 3 | En marcha, sin reclutar | may 2024 (real) |
Todos los de GILD, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT01915472), actualizada en ago 2021.